Key Points
- CEO John Kao sold 605,648 shares on Dec. 29 at an average price of $18.74 for about $11.35 million, leaving him with 2,234,294 shares — a 21.33% reduction in his stake.
- Other insiders including President Dawn Maroney (282,070 shares) and several executives also sold shares at $18.74, a cluster of sizable insider dispositions that could weigh on investor sentiment.
- Alignment recently beat quarterly EPS expectations and reported revenue up 43.5% year‑over‑year, but still shows a small negative net margin (‑0.57%) and negative ROE (‑16.23%); analysts rate the stock a "Moderate Buy" with a consensus target of $20.35.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Hyong Kim sold 12,694 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $18.74, for a total transaction of $237,885.56. Following the completion of the sale, the insider directly owned 349,639 shares in the company, valued at approximately $6,552,234.86. This represents a 3.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Hyong Kim also recently made the following trade(s):
- On Thursday, October 9th, Hyong Kim sold 51,379 shares of Alignment Healthcare stock. The stock was sold at an average price of $17.57, for a total transaction of $902,729.03.
- On Wednesday, October 8th, Hyong Kim sold 33,655 shares of Alignment Healthcare stock. The shares were sold at an average price of $17.29, for a total transaction of $581,894.95.
Alignment Healthcare Stock Performance
Alignment Healthcare stock opened at $19.24 on Wednesday. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. The firm has a market capitalization of $3.85 billion, a P/E ratio of -160.33 and a beta of 1.16. Alignment Healthcare, Inc. has a 1-year low of $11.01 and a 1-year high of $21.06. The company's 50-day moving average is $18.22 and its 200 day moving average is $16.22.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. The business had revenue of $993.70 million during the quarter, compared to analyst estimates of $980.90 million. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The company's revenue for the quarter was up 43.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.14) earnings per share. Research analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.
Hedge Funds Weigh In On Alignment Healthcare
A number of hedge funds and other institutional investors have recently bought and sold shares of ALHC. Raymond James Financial Inc. lifted its position in Alignment Healthcare by 31.1% during the 1st quarter. Raymond James Financial Inc. now owns 206,174 shares of the company's stock worth $3,839,000 after acquiring an additional 48,901 shares during the period. Strs Ohio purchased a new position in Alignment Healthcare in the 1st quarter valued at $600,000. Inspire Investing LLC acquired a new position in Alignment Healthcare in the 3rd quarter valued at $1,129,000. Ameritas Investment Partners Inc. raised its position in Alignment Healthcare by 32.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 13,031 shares of the company's stock worth $182,000 after buying an additional 3,225 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Alignment Healthcare by 1,025.2% during the 1st quarter. Acadian Asset Management LLC now owns 375,949 shares of the company's stock worth $6,992,000 after buying an additional 342,537 shares during the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
ALHC has been the subject of several research analyst reports. UBS Group lifted their target price on Alignment Healthcare from $17.00 to $18.00 and gave the stock a "neutral" rating in a research report on Friday, October 31st. KeyCorp reissued an "overweight" rating on shares of Alignment Healthcare in a research report on Monday, November 24th. JPMorgan Chase & Co. upped their target price on shares of Alignment Healthcare from $20.00 to $23.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of Alignment Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, November 8th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $22.00 price target on shares of Alignment Healthcare in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.35.
Read Our Latest Report on Alignment Healthcare
Alignment Healthcare News Roundup
Here are the key news stories impacting Alignment Healthcare this week:
- Positive Sentiment: Baird published a note saying Alignment Healthcare "should be bought on recent selloff," which can attract value-oriented buyers and help lift the stock. Baird Buy Note
- Negative Sentiment: CEO John E. Kao sold 605,648 shares at an average price of $18.74 (~$11.35M), a 21.33% reduction in his holding — a large, high‑profile insider sale that can be read as a negative signal for sentiment. Kao SEC Filing
- Negative Sentiment: President Dawn Christine Maroney sold 282,070 shares at $18.74 (~$5.29M), cutting her stake by ~16.9% — another sizable insider disposition that can weigh on investor confidence. Maroney SEC Filing
- Negative Sentiment: Other insider sales include Robert L. Scavo (69,541 shares), Christopher J. Joyce (16,187 shares) and Hyong Kim (12,694 shares), each sold at $18.74 — smaller individually but collectively add to the sell-side signal. Scavo SEC Filing Joyce SEC Filing Kim SEC Filing
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
